Simple surface EMG recording as a noninvasive screening method for the detection of acute oxaliplatin-induced neurotoxicity: a feasibility pilot study

Heuvel, Sandra A S van den; Doorduin, Jonne; Steegers, Monique A H; Bronkhorst, Ewald M.; Radema, Sandra A.; Vissers, Kris; Wal, Selina E I van der; Alfen, Nens van

doi:10.1016/j.neulet.2019.02.014

Cited by 6 publications

(3 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, rapid non-invasive corneal confocal microscopy, LDI (laser Doppler imager) technology, and surface electromyography recording are also methods that can be used to confirm the diagnosis of CIPN in patients [ 22 , 28 – 30 ] (Table 3 ). The combination of artificial intelligence (AI) with the traditional scales may be important in the management and understanding of the epidemiology of OIPN [ 31 , 32 ].…”

Section: The Clinical Syndrome: Classification and Characteristics Clinical Diagnosis Risk Factors And Genetic Polymorphisms With Oipnmentioning

confidence: 99%

Targeting strategies for oxaliplatin-induced peripheral neuropathy: clinical syndrome, molecular basis, and drug development

Yang

Zhao

Gao

et al. 2021

J Exp Clin Cancer Res

View full text Add to dashboard Cite

Oxaliplatin (OHP)-induced peripheral neurotoxicity (OIPN) is a severe clinical problem and potentially permanent side effect of cancer treatment. For the management of OIPN, accurate diagnosis and understanding of significant risk factors including genetic vulnerability are essential to improve knowledge regarding the prevalence and incidence of OIPN as well as enhance strategies for the prevention and treatment of OIPN. The molecular mechanisms underlying OIPN are complex, with multi-targets and various cells causing neuropathy. Furthermore, mechanisms of OIPN can reinforce each other, and combination therapies may be required for effective management. However, despite intense investigation in preclinical and clinical studies, no preventive therapies have shown significant clinical efficacy, and the established treatment for painful OIPN is limited. Duloxetine is the only agent currently recommended by the American Society of Clinical Oncology. The present article summarizes the most recent advances in the field of studies on OIPN, the overview of the clinical syndrome, molecular basis, therapy development, and outlook of future drug candidates. Importantly, closer links between clinical pain management teams and oncology will advance the effectiveness of OIPN treatment, and the continued close collaboration between preclinical and clinical research will facilitate the development of novel prevention and treatments for OIPN.

show abstract

Section: The Clinical Syndrome: Classification and Characteristics Clinical Diagnosis Risk Factors And Genetic Polymorphisms With Oipnmentioning

confidence: 99%

Targeting strategies for oxaliplatin-induced peripheral neuropathy: clinical syndrome, molecular basis, and drug development

Yang

Zhao

Gao

et al. 2021

J Exp Clin Cancer Res

View full text Add to dashboard Cite

show abstract

“…The Common Terminology Criteria for Adverse Events from the National Cancer Institute (NCI.CTC) [ 10 , 44 , 50 ], the oxaliplatin-specific neurotoxicity scale [ 51 ], or a score based on recording the frequency of symptoms with an OXA-Neuropathy Questionnaire (yes/no response format) [ 17 , 52 , 53 ], are among the most common systems for recording their presence in the daily practice. The severity of acute neurotoxicity syndrome has been defined according the burden of symptoms [ 54 ], or according to a visual analogical scale 0 (no problem) to 10 (major problem) numerical rating scale for any of the four acute neuropathy symptoms [ 48 , 55 , 56 ]. More sophisticated techniques to objectively assess acute syndrome are described below in detail.…”

Section: Clinical Factors Associated With Oxaipnmentioning

confidence: 99%

“…However, the invasive nature of nEMG hampers its feasibility as screening tool to monitor gastrointestinal cancer patients undergoing OXA. Very recently, a simple painless objective tool to detect nerve hyperexcitability acute syndrome by a surface electromyography (sEMG) has been tested in a small study including CRC patients after the second ( n = 14) and fourth ( n = 8) OXA infusions revealing that sEMG is more sensitive (82%) than neurological examination (55%) to detect objective signs of acute neurotoxicity [ 55 ]. As such sEMG might be a promising test to evaluate acute oxaliplatin-induced motor nerve hyperexcitability and warrants to be further investigated in future studies.…”

Section: Neurophysiological and Device-dependent Predictorsmentioning

confidence: 99%

Predictive Biomarkers of Oxaliplatin-Induced Peripheral Neurotoxicity

Velasco

Alemany

Villagrán

et al. 2021

JPM

View full text Add to dashboard Cite

Oxaliplatin (OXA) is a platinum compound primarily used in the treatment of gastrointestinal cancer. OXA-induced peripheral neurotoxicity (OXAIPN) is the major non-hematological dose-limiting toxicity of OXA-based chemotherapy and includes acute transient neurotoxic effects that appear soon after OXA infusion, and chronic non-length dependent sensory neuronopathy symmetrically affecting both upper and lower limbs in a stocking-and-glove distribution. No effective strategy has been established to reverse or treat OXAIPN. Thus, it is necessary to early predict the occurrence of OXAIPN during treatment and possibly modify the OXA-based regimen in patients at high risk as an early diagnosis and intervention may slow down neuropathy progression. However, identifying which patients are more likely to develop OXAIPN is clinically challenging. Several objective and measurable early biomarkers for OXAIPN prediction have been described in recent years, becoming useful for informing clinical decisions about treatment. The purpose of this review is to critically review data on currently available or promising predictors of OXAIPN. Neurological monitoring, according to predictive factors for increased risk of OXAIPN, would allow clinicians to personalize treatment, by monitoring at-risk patients more closely and guide clinicians towards better counseling of patients about neurotoxicity effects of OXA.

show abstract

Oxaliplatin-induced peripheral neuropathy: clinical features, mechanisms, prevention and treatment

et al. 2020

View full text Add to dashboard Cite

Simple surface EMG recording as a noninvasive screening method for the detection of acute oxaliplatin-induced neurotoxicity: a feasibility pilot study

Cited by 6 publications

References 32 publications

Targeting strategies for oxaliplatin-induced peripheral neuropathy: clinical syndrome, molecular basis, and drug development

Targeting strategies for oxaliplatin-induced peripheral neuropathy: clinical syndrome, molecular basis, and drug development

Predictive Biomarkers of Oxaliplatin-Induced Peripheral Neurotoxicity

Oxaliplatin-induced peripheral neuropathy: clinical features, mechanisms, prevention and treatment

Contact Info

Product

Resources

About